Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2020-06-19 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT TO CREDITORS OF THE COMPANY IN RELATION TO GENERAL MANDATE GRANTED TO THE BOARD TO REPURCHASE H SHARES OF THE COMPANY
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to disclosure requirements under the Hong Kong Stock Exchange rules. It informs creditors about the general mandate granted to the board to repurchase H shares and provides instructions for creditors to claim their rights. The document does not contain financial statements or detailed financial data but is a regulatory announcement related to a corporate action (share repurchase mandate) and creditor notification. It is not a full report like an annual or interim report, nor is it a call transcript or management report. It is also not a direct announcement of voting results or a dividend notice. The document is a formal regulatory announcement informing stakeholders about the repurchase mandate and creditor claims, fitting best under Regulatory Filings (RNS). The document length is just under 5,000 characters, and it is a standalone announcement, not a report publication notice. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-06-19 English
CHANGE OF EMPLOYEE REPRESENTATIVE DIRECTOR AND EMPLOYEE REPRESENTATIVE SUPERVISOR
Board/Management Information Classification · 95% confidence The document is an announcement from Yanzhou Coal Mining Company Limited regarding changes in the company's employee representative director and employee representative supervisors. It details the cessation of terms and election of new directors and supervisors, including biographical information and confirmations of no disagreements or issues. The document references compliance with the Hong Kong Listing Rules and provides no financial data or report content. It is a formal announcement about board and supervisory committee personnel changes, not a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length (10,717 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2020-06-19 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, specifically detailing changes in issued share capital and share buybacks. It includes detailed tables of share repurchases, confirmations of compliance with listing rules, and notes explaining the context of share issues and repurchases. The document is regulatory in nature, reporting on share capital changes and repurchase activities, but it is not a full financial report, earnings release, or management discussion. It is a formal disclosure related to share capital changes and repurchases, fitting the category of Transaction in Own Shares (POS). The document length (8700 characters) and content confirm it is a detailed disclosure rather than a brief announcement or certification only.
2020-06-18 English
VOLUNTARY ANNOUNCEMENT - CSTONE'S PARTNER BLUEPRINT MEDICINES PRESENTED UPDATED PART 1 DATA FROM PIONEER TRIAL OF AVAPRITINIB SHOWING ROBUST REDUCTIONS IN CUTANEOUS DISEASE SYMPTOMS IN PATIENTS W
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding updated clinical trial data presented by their partner Blueprint Medicines. It discusses updated data from the PIONEER trial of avapritinib, including clinical activity, safety data, and plans for future trial phases. The document is an announcement of clinical trial results and presentation details, not a full financial or regulatory report. It does not contain financial statements, audit information, or detailed management discussion. It is also not a transcript, capital update, or legal proceeding report. The document is a regulatory announcement informing the market about clinical data updates and upcoming presentations, typical of a Regulatory Filings (RNS) category. The document length (10,402 characters) and content support this classification rather than a full report or presentation.
2020-06-17 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, specifically detailing changes in issued share capital and share buybacks by CStone Pharmaceuticals. It includes detailed tables of share repurchases, confirmations of compliance with listing rules, and specifics about the number of shares repurchased and prices paid. The content focuses on share repurchase activities and changes in issued share capital, which aligns with announcements regarding share buybacks or capital changes. There is no indication that this is a full financial report, audit, or earnings release. The document is not a report publication announcement or a certification letter but a regulatory disclosure about share capital changes and repurchases. Therefore, the most appropriate classification is Transaction in Own Shares (POS).
2020-06-17 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, specifically detailing changes in issued share capital and share buybacks. It includes detailed tables of share repurchases, issue prices, and confirmations related to compliance with listing rules. The content focuses on reporting share repurchase transactions and changes in issued shares, which aligns with announcements regarding share repurchases or capital changes. There is no indication of a full financial report, earnings release, or management discussion. The document is not a report publication announcement but a regulatory disclosure of share capital changes and repurchases. Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS). The document length (8619 characters) supports it being a substantive disclosure rather than a brief announcement. Confidence is high due to the clear focus on share repurchases and issued share capital changes.
2020-06-16 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.